Year: 2024
Type: article
Abstract: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents the latest threat to global health security, and the pressure to identify effective therapeutics during this pandemic is immense. This stress has led to the use of unproven therapies with greater than minimal risk. One example is the use of IL-6 receptor antagonists. After an early report of a “cytokine storm” in patients with coronavirus disease (COVID-19), there is increased interest in anti–IL-6 therapy as a treatment option, with ill-defined criteria for use (1).
DOI: 10.17615/5cx4-wf37
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4401040852